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Background: Intravitreal injection of human mesenchymal stem cells has been shown to be 
effective in slowing the progression of diabetic retinopathy in an animal model of chemically 
induced diabetes mellitus. We studied changes in growth factor levels released from human 
mesenchymal stem cells in the vitreous cavity as well as changes in growth factor levels in host 
retinal neurons following intravitreal injection.
Methods: Twenty-two Lewis rats were treated with an intravitreal human mesenchymal stem 
cell microinjection. Determination of neurotrophic factors released by human mesenchymal 
stem cells in the vitreous was carried out using real-time polymerase chain reaction.
Results: Detectable levels of neurotrophic factors were identified postoperatively in the vitre-
ous of all rats.
Conclusion: Increased intravitreal and retinal concentrations of neuroprotective growth fac-
tors in rats confirm the neuroprotective activity of human mesenchymal stem cells in diabetic 
retinopathy.
Keywords: diabetic retinopathy, neuroprotection, apoptosis mechanism, stem cells, chemically 
induced diabetes mellitus
Introduction
Stem cells are nonspecialized cells capable of dividing and simultaneously giving rise 
to both new stem cells and precursors of a cell progeny which then develop into mature 
cells. Stem cells are classified into four groups, ie, embryonic, germinal embryonic, 
placental (umbilical cord), and adult cells. Human stem cells represent a large reservoir 
of anti-apoptotic and antineoangiogenic growth factors, and there is growing interest 
in the ophthalmologic field regarding the use of human stem cells in the management 
of a group of retinal diseases1,2 induced and supported by apoptotic and neoangiogenic 
mechanisms and mediated by proinflammatory growth factors, such as cytokines, 
chemokines, and vascular endothelial growth factor. In this study, we used placental 
human stem cells given that the placenta,3 specifically the amniotic membrane,4 
  represents an important source of human stem cells because of the abundance of cells 
which can be recovered and also the absence of ethical issues, considering that the 
placenta is a waste product.5 Histological study of placental tissue has shown that the 
amniotic membrane is made up of a layer of amniotic epithelial cells resting on a basal 
membrane and, more externally, on a stroma of connective tissue or amniotic mesoderm 
in which there are amnion mesenchymal stromal stem cells. The cells extracted from Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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the placenta6 have an important immunomodulatory function. 
This property is due to the lack of the major histocompatibility 
complex II and to the expression of both costimulatory 
molecules in the membrane and of human leukocyte 
antigen G.7 Molecular analysis of factors expressed by 
amnion epithelial cells demonstrate that these cells express 
factors in common with specific membrane markers for 
human embryonic stem cells, such as octamer-binding 
transcription factor 4, a transcription factor essential for 
maintaining self-renewal of undifferentiated embryonic 
stem cells, and also produce fibroblast growth factor 4, 
which is encoded by the fibroblast growth factor gene and 
possesses broad mitogen and cell survival features. 
Furthermore, these human embryonic stem cells demon-
strate positivity for stage-specific embryonic antigen 3 
and 4, tumor rejection antigen 1–60 and 1–81, human proto-
oncogene c-kit (a cell surface antigen), and nestin (a tran-
scription factor critically involved in self-renewal of 
undifferentiated embryonic stem cells and their 
multipotency). Human embryonic stem cells do not express 
the stage-specific embryonic antigen 1 or the hematopoietic 
stem cell marker, CD34. Their proliferative capacity can 
be maintained in culture in Dulbecco’s Modified Eagle 
Medium with 10% fetal bovine serum and epidermal growth 
factor. The aim of our research was to assess the tolerability 
and effectiveness of transplanted human placental stem 
cells in a rat model of chemically induced type 2 diabetes 
mellitus.8 The functional capacity of the transplant in pre-
venting and/or slowing the progression of diabetic retin-
opathy was evaluated by measuring the neuroprotective, 
anti-apoptotic, and anti-angiogenic effects of growth factors 
liberated from human stem cells, and their possible role in 
slowing or blocking the retinal neoangiogenic process. 
Evolution of type 2 diabetes mellitus in a rat model was 
assessed daily using the glycemia index, water consump-
tion, and variations in body weight, in order to identify the 
benefits of human placental stem cell therapy on the pro-
gression of diabetes.9 Diabetic retinopathy, in particular 
proliferative diabetic retinopathy, is characterized by pre-
retinal neovascularization and fibrosis, vitreous hemor-
rhage, and tractional retinal detachment. Many authors 
believe that a great variety of proapoptotic growth factors, 
eg, vascular endothelial growth factor, are involved in 
activating and perpetuating the neovascular process. Many 
studies have demonstrated that the levels of many angio-
genic factors are higher in the vitreous of patients affected 
by proliferative diabetic retinopathy than those in individu-
als without vasoproliferative retinopathies.
Methods
This preliminary interdisciplinary multicenter study was 
supported by the University of Bologna and carried out by 
the Department of General Surgery and Organ Transplants 
at the University of Bologna in collaboration with the Depart-
ment of Ophthalmology at the University of Naples, and with 
the support of the Department of Ophthalmology at the US 
Army Health Clinic Camp Darby of Livorno. This study was 
approved by the ethical committee at the Sant’Orsola- 
Malpighi Hospital, University of Bologna, and all procedures 
were carried out under an institutionally approved protocol 
in accordance with the ethical principles and standards of 
the Federation of European Animal Science Association, 
following the guidelines of the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals and the 
current legislation on preclinical research in Italy. All the 
regulations of the Centralized Veterinary Service of Bologna 
were respected. Fifteen young adult male syngenetic Lewis 
rats, weighing 180–200 g (mean 188.56 ± standard deviation 
[SD] 7.14 g) were included in this randomized preclinical 
study and were rendered diabetic using streptozotocin.
Glycemia10 was set at 90–120 (mean 98.3 ± 3.4) mg/dLat 
baseline (time 0, beginning of the study). Animals which did 
not meet these requirements were excluded. All rats selected 
for study were further subdivided into two groups, ie, Group 
A and Group B. Group A (n = 12) underwent an intravitreal 
human placental stem cell implant, and Group B (n = 3) 
served as the control. The rats in both groups were rendered 
diabetic by a single intraperitoneal injection of strep-
tozotocin11 65 mg/kg. Starting from the day after streptozo-
tocin injection, evening glycemia was evaluated daily and 
rats with a glycemia index $250 mg/dL for 3 consecutive 
days were considered to have developed type 2 diabetes 
mellitus. Chemically-induced diabetes in this rat model was 
monitored by a glycemic check in both groups, taking daily 
blood samples from the caudal vein. Consumption of water 
and variation in bodyweight were also recorded. Rats treated 
with streptozotocin demonstrated a marked increase in daily 
water consumption up to 150–200 (mean 163.99 ± 1.9) mL/day 
21 days after injection, while control values were 
20–23 mL/day. Streptozotocin-treated diabetic rats reached 
glycemiclevels of 250–350 (mean 301.87 ± 4.1) mg/dL 
21 days after injection whereas the nondiabetic rats had 
glycemic levels of 110–130 mg/dL. Treatment with strepto-
zotocin also interrupted growth (see Figure 1). At 21 days 
after treatment with streptozotocin, all rats in Group A 
received an intravitreal transplant of human placental stem 
cells. Rats in Group B (sham-operated) were not treated, and Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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were just monitored for water consumption, glycemia index, 
and bodyweight changes, in order to control the evolution of 
type 2 diabetes. The cell populations we transplanted were 
representative of human placental stem cells, ie, having 
elevated staminality, and were isolated from healthy placental 
tissue at term. We observed and studied the in vitro potential 
of these cell populations to differentiate into retinal pheno-
types, with the aim of evaluating the differentiation potential 
of these cells in a diabetic animal model. In our study, we 
injected adult mesenchymal stem cells into the vitreous of 
the diabetic rats. Adult mesenchymal stem cells have a vast 
differentiation potential, with suppressive immunomodula-
tory activity via expression of immunomodulatory molecules, 
such as human leukocyte antigen G and interleukin-10. 
Moreover, adult mesenchymal stem cells were capable of 
inserting into rat tissue without inducing rejection phenomena. 
The cell populations were tagged with fluorescent markers 
in order to differentiate between them for in vivo transplantation. 
The markers we used were carbocyanine dyes with 
hydrophilic/hydrophobic characteristics. These dyes are usu-
ally used in living tissues and cells because they insert into 
the membrane and diffuse rapidly, staining the entire cell 
surface. We used 3,3´-dioctadecyloxacarbocyanine and   
1-1´-dioctadecyl – 3,3,3´,3´ tetramethy 1 indodicarbocyanine. 
The advantages of these dyes are their manageability and 
thermal stability. Release of insulin in response to elevated 
glucose  concentrations  was  tested  in  vitro  using 
radioimmunoassay. One week before treating the animals, 
in vitro expansion of the human placental stem cells was 
carried out in culture. This procedure allowed us to maintain 
a stable phenotype with a high proliferative capacity. 
Characterization of the human placental stem cells and 
their differentiating potential was then performed by 
cytofluorimetric analysis. The profile of genetic expression 
was also studied in relation to nerve growth factor, brain-
derived neurotrophic factor, ciliary-derived neurotrophic 
factor, glial-derived neurotrophic factor, and basic fibroblast 
growth factor.12,13 The day before intravitreal transplant, the 
human placental stem cells were trypsinized with 1 mL of 
trypsin, after aspiration of the culture medium and having 
washed the cells with about 3 mL of phosphate-buffered 
saline. After approximately 1 minute, the cells began to detach 
and were then stained with 3,3´-dioctadecyloxacarbocyanine 
fluorescent dye and resuspended in serum-free medium 
supplemented with epidermal growth factor and basic fibro-
blast growth factor at a concentration of 50,000 cells/ µL. 
The cells were kept on ice for 4 hours before transplanting. 
Before receiving the transplant, Equithesin® was adminis-
tered to all diabetic rats in Group A for general anesthesia.14 
Equithesin was prepared according to the doses reported in 
Table 1, adhering to the order of components as listed. 
Before adding each successive component, a check was 
performed to ensure that each preceding component was 
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Figure 1 Variation in water consumption and glycemia after treatment with streptozotocin. rats treated with streptozotocin demonstrated a notable increase in daily 
water consumption, up to values of 150–200 mL/day at 21 days after treatment (mean 163.99 ± 1.9 mL/day), while reference values were 20–23 mL/day. rats treated with 
streptozotocin reached mean glycemic levels of 250–350 mg/dL at 21 days after treatment (301.87 ± 4.1 mg/dL) unlike the nondiabetic rats (standard values 110–130 mg/dL).
Table  1  equithesin®  anesthesia.  equithesin  was  prepared 
according to the doses reported, respecting the order of the 
components. Before adding each successive component, it was 
necessary  to  check  that  each  preceding  component  was  well 
dissolved. The dose administered was 0.4 mL/100 g, adjusted in 
relationship to the weight of each individual rat
Component Dose
h2O distilled 20 mL
Propylene glycol 19.8 mL
ethanol 5 mL
Sodium pentobarbital 0.4860 g
Magnesium sulfate 1.0625 g
Chloral hydrate 2.1245 gClinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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well dissolved. The dose administered was 0.4 mL/100 g, 
adjusted for the weight of each individual rat. Before the 
surgical procedure, each rat was settled on a stereotactic 
table, and a single drop of iodopovidone 10% was instilled 
into the conjunctival sac to disinfect the periorbital and 
periocular skin, thereby preventing onset of endophthalmitis. 
After 5 minutes, another drop of iodopovidone 5% was 
instilled into the eye. When performing the surgical proce-
dure, a microinjector pump connected to a flow rate system 
was used to control the flux of human placental stem cells, 
so that a maximum concentration of stem cells could be 
reached in the vitreous. The flow rate was maintained at 
50,000 cells/µL. Intravitreal injection of the resuspended 
human placental stem cells was carried out via the pars 
planaat the level of the inferotemporal quadrant, 1 mm from 
the limbus. A drop of iodopovidone 5% was instilled in the 
operated eye after the intravitreal stem cell implant. The 
animals were monitored during postoperative reawakening 
and daily in the 7-day postsurgical period, to be able to 
identify any signs of suffering as early as possible. 
Postoperative discomfort was minimal. Evaluation of the 
diabetic rats in group B (sham operated) was also performed; 
the same surgical procedure was carried out in these rats 
using 0.2 µL physiological solution only. Immediately after 
the intravitreal transplant, all the rats were started ontopical 
antibiotic prophylaxis using tobramycin eye drops, instilling 
one drop in each operated eye three times daily for 10 days 
postoperatively. On postoperative day 21, all the diabetic rats 
in Group A underwent fluorangiography examination for 
clinical evaluation of diabetic retinopathy. Diabetic rats in 
Group B underwent the same examination. Fluorescein was 
injected at the caudal level. We evaluated the diabetic retin-
opathy from a clinical point of view in order to assess the 
eventual stabilization/regression of diabetic retinopathy, 
paying particular attention to retinal neovascularization and 
other signs of disease. This evaluation demonstrated the 
presence of neovascularization, ischemic areas, and microa-
neurysms present in the retina of the Group B diabetic rats. 
Moreover, vitreous levels of anti-apoptotic growth factors 
were quantified by real-time polymerase chain reaction using 
an enzyme-linked immunosorbent assay kit for vitreous 
growth factors. Multiplex bead assays were used for measure-
ment of different growth factors and cytokines, in particular 
levels of basic fibroblastic growth factor, nerve growth factor, 
brain-derived neurotrophic factor, ciliary-derived neuro-
trophic factor,15 and glial-derived neurotrophic factor in the 
vitreal chamber. The increase in the levels of these factors in 
rats with transplanted human stem cells underscore the 
potential neuroprotective effects against oxidative damage of 
  high growth factor levels released from stem cells.16–18 Vitre-
ous samples (0.2 µL each sample) were used undiluted and 
immediately, in order to avoid vitreous condensation and 
solidification. Real-time polymerase chain reaction was per-
formed according to the manufacturer’s instructions. Because 
of the limited volume of some of the samples, a minimum of 
duplicate tests were undertaken for each assay. Saline was 
substituted for the vitreous implant in the negative controls.
Statistical analysis
Statistical analysis was performed on all data using analysis 
of variance on XLSTAT2010 software (Addinsoft USA, 
New York). The level of statistical significance was set 
at P , 0.05.
Results
Fluorangiography examination showed that rats receiving the 
intravitreal human placental stem cell transplant had a marked 
improvement in the evolution of diabetic retinopathy. Group 
A showed markedly decreased areas of hypofluorescence and 
hypoperfusion, due to the ischemia leading to evolution of 
diabetic retinopathy and absence of leakage phenomena, 
which indicates slowing and/or stabilization of diabetic   
retinopathy. On fluorangiographic examination, Group B rats 
demonstrated retinal hyperfluorescence (leakage) associated 
with significant areas of hypofluorescence, and microaneu-
rysms, neovascularization, and ischemic areas, both   
preoperatively and postoperatively. The fluorangiographic 
examination was strictly qualitative, so was performed by the 
same operator to reduce the chances of observational errors. 
Moreover, determination of neurotrophic and growth factors 
having an anti-apoptotic, antineoangiogenic, and neuroprotec-
tive role and released by the transplanted human placental 
stem cells in Group A were evaluated using vitreous real-time 
polymerase chain reaction. The growth factors released were 
ligands of two large families of receptors, ie, the family of 
transmembrane receptors with tyrosine kinase activity and 
the family of neurotrophic receptors. The growth factors we 
evaluated were basic fibroblastic growth factor, nerve growth 
factor, brain-derived neurotrophic factor, ciliary-derived 
neurotrophic factor, and glial-derived neurotrophic factor. All 
these growth factors were detected in all vitreous samples 
tested. Real-time polymerase chain reaction showed notable 
levels of vitreous expression of neurotrophic factors. 
Qualitative and quantitative analysis of these factors showed Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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that the greatest peaks of   concentration at the endovitreal level 
were reached by brain-derived neurotrophic factor and ciliary-
derived neurotrophic factor in rats with transplanted human 
stem cells. Significantly higher levels of basic fibroblast 
growth factor, nerve growth factor, brain-derived neurotrophic 
factor, ciliary-derived neurotrophic factor, and glial-derived 
neurotrophic factor were observed in the vitreous samples of 
rats in group A compared with Group B controls. All neuro-
protective growth factor levels were significantly higher 
(P , 0.05) in rats affected by diabetic retinopathy and with 
transplanted human stem cells than in Group B controls. Both 
brain-derived neurotrophic factor and ciliary-derived neu-
rotrophic factor reached levels of 107.99 pg/mL ± 0.002 
(P, 0.05) in Group A rats, while the median level of brain-
derived neurotrophic factor and ciliary-derived neurotrophic 
factor in Group B controls was 38.7 pg/mL ± 0.023. This 
difference was statistically significant (P , 0.05). Furthermore, 
a significant negative association was observed between 
vascular endothelial growth factor and proinflammatory 
cytokine levels and the progression of the diabetic retinopathy 
after transplantation in Group A rats (Figure 2).
Discussion
We had not been optimistic that a single stem cell injection 
could provide enough antioxidant activity to have detectable 
effects on the development of diabetic retinopathy in an 
animal model. Therefore, we were surprised to find that a 
single intravitreal injection of human placental stem cells 
resulted in a significant decrease of retinal apoptosis in rats 
rendered diabetic by means of a single injection of 
streptozotocin compared with the controls. This preliminary 
study provides additional support for the hypothesis that 
oxidative damage is an important contributor to retinal dam-
age in diabetic retinopathy.19 Critical analysis of the results 
shows that human placental stem cells currently represent 
the safest and most controlled biological pathway for the 
release of chemical mediators, such as growth factors with 
specific anti-apoptotic and antineoangiogenic roles, in an 
animal model of diabetes mellitus. The procedure we used 
allowed control of progression of chemically induced diabetic 
retinopathy. Furthermore, no deaths, rejection, intolerance 
phenomena, or postoperative complications were encoun-
tered, nor were any adverse reactions encountered on fluo-
rangiographic examination. This study describes a simple 
methodology with possible clinical implications for humans 
in the future. Our finding that a decrease in retinal apoptotic 
phenomena and oxidative damage contributes to preventing 
development of diabetic retinopathy in rats has important 
clinical implications. Moreover, this challenging approach 
to the treatment of diabetic retinopathy using an animal model 
has several advantages, in that it is simple to perform, is not 
surgeon-dependent, is portable and relatively inexpensive, 
is not as invasive as other surgical techniques, and gives a 
rapid and very good response. We did not identify any dis-
advantages, and no side effects or rejection phenomena were 
noticed during the study. It provides a therapeutic target that 
may apply in the future to patients affected by this disease. 
The clinical and genetic heterogeneity that constitutes dia-
betic retinopathy is a problem when attempting to develop 
treatments targeting the primary defect involved in 
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this disorder. The documented slowing down of diabetic 
retinopathy in this animal model, as well as the antineoan-
giogenic effects, indicates an effective neuroprotective and 
anti-inflammatory role at the retinal level. The increased 
concentrations of neuroprotective growth factors seen in the 
vitreous camera following intravitreal injection of stem cells, 
allow us to hypothesize a possible neuroretinal protective 
role for these factors. Additional studies are necessary in 
order to expand upon these results so as to make this thera-
peutic approach relevant to humans. Human placental stem 
cells taken from a healthy placenta at term and implanted in 
the vitreous chamber by simple intravitreal injection could 
be an attractive and innovative therapeutic option in the 
management of diabetic retinopathy. Furthermore, in this 
way, trauma at the ocular level could be avoided. The interest 
shown by ophthalmologists in this retinal pathology has 
grown exponentially, given the epidemiological importance 
of diabetic retinopathy, which is the retinal pathology associ-
ated with the highest rate of blindness in Italy and in the rest 
of the world, and given the absence of long-term definitive 
therapeutic approaches. It will be necessary to increase the 
number of researchers involved in our study group to reach 
the clinical phase of experimentation for this pathology in 
the future.20,21
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